New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)

Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: E. L. Nasonov, A. S. Avdeeva, T. V. Popkova
Formato: Artigo
Lenguaje:Russo
Publicado: IMA-PRESS LLC 2021-10-01
Colección:Научно-практическая ревматология
Materias:
systemic lupus erythematosus
interferon
genetically engineered biological drugs
anifrolumab
Acceso en línea:https://rsp.mediar-press.net/rsp/article/view/3072
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares